Key Takeaways

  • Immutep (ASX: IMM) shares rose roughly 13.73% to $0.06 in the morning session on 13 July 2026 (snapshot near 11.04am AEST, 20-minute delayed data), and intraday prices can shift through the day.
  • No fresh, company-specific announcement was identified in the available material at the time of writing to explain the move.
  • The ASX Health Care sector index was down about 0.82% that morning, so Immutep rose against its sector rather than on broad healthcare strength.
  • Immutep is a LAG-3 immunotherapy developer; its Phase III TACTI-004 lung cancer trial for lead candidate eftilagimod alfa was discontinued for futility in March 2026, reshaping the investment case.
  • The company reported A$110.6 million in cash and term deposits at 31 March 2026, with runway stated into the first half of calendar 2028, though clinical, funding and regulatory risks remain material.

Immutep Limited attracted outsized attention on the Australian share market on Monday 13 July 2026, with its stock rising about 13.73% to $0.06 in the morning session. The figures are drawn from a market snapshot captured around 11.04am AEST on 20-minute delayed data, and it is worth stressing at the outset that intraday moves of this kind are not settled outcomes; the price could ease back, extend, or reverse before the session closes.

The scale of the percentage gain deserves context. Immutep trades at a very low nominal price, and at these levels a movement of a fraction of a cent can translate into a double-digit percentage change. That mechanical sensitivity is a defining feature of low-priced, speculative stocks, and it means a large-looking headline gain can rest on a comparatively small shift in the underlying quote.

What Happened to the Immutep Share Price

On the morning of 13 July 2026, Immutep sat near the top of the day's gainers, up about 13.73% at $0.06. That placed it among a cluster of health-adjacent names drawing buying interest, even as the overall market drifted, with the S&P/ASX 200 modestly lower around the same time.

Crucially, the move was not accompanied by any fresh, company-specific announcement that could be identified in the available material at the time of writing. In the absence of a verified catalyst, the surge is best read as a market-driven or sentiment-driven move rather than a response to newly disclosed news from the company. Investors and observers may treat single-session gains in thinly traded, low-priced biotech shares with particular caution, since they can be amplified by modest order flow.

Company Overview: Who Immutep Is

Immutep Limited is a clinical-stage biotechnology company focused on Lymphocyte Activation Gene-3 (LAG-3), an immune-system checkpoint that has become a significant area of research in immuno-oncology and autoimmune disease. The company positions itself as a specialist in LAG-3 biology, developing product candidates that either activate or modulate the immune response depending on the therapeutic goal.

The business straddles two broad ambitions. In oncology, it has sought to harness LAG-3 to stimulate a stronger anti-cancer immune response. In autoimmune and inflammatory disease, it is pursuing the opposite mechanism, aiming to dampen overactive immune activity. That dual approach gives Immutep exposure to two large therapeutic areas, though it also spreads development risk across distinct clinical and regulatory pathways.

Pipeline and Product Candidates

Immutep's most advanced oncology asset is eftilagimod alfa, known as efti, a first-in-class soluble LAG-3 protein designed to act as an antigen-presenting cell activator. Efti has been studied in combination with checkpoint inhibitors and chemotherapy across several tumour types, positioning it as a potential complement to existing immunotherapy backbones rather than a standalone treatment.

The company's headline Phase III programme for efti was TACTI-004, a registrational trial in first-line, advanced or metastatic non-small cell lung cancer, testing efti alongside pembrolizumab and chemotherapy. In March 2026, however, Immutep announced that TACTI-004 would be discontinued following a planned interim futility analysis, after the trial's Independent Data Monitoring Committee recommended stopping on the basis of the available safety and efficacy data. That decision materially altered the near-term outlook for the efti lung cancer opportunity and prompted a root-cause review of the broader efti programme.

Beyond efti, Immutep has advanced IMP761, described as a first-in-class LAG-3 agonist antibody aimed at autoimmune disease. In June 2026, the company reported positive interim Phase I data for IMP761 at the EULAR 2026 congress in London, pointing to statistically significant pharmacodynamic activity, including a reduction in local inflammatory responses at higher dose levels compared with placebo. Those early findings are from a first-in-human study and remain to be confirmed in larger, later-stage trials, but they have kept the autoimmune programme in focus for investors weighing the company's diversification beyond oncology.

Financial Position and Cash Runway

For a pre-revenue biotechnology company, the balance sheet is central to the investment case, because it determines how long management can fund research before needing to raise fresh capital. In its quarterly activities report for the quarter ended 31 March 2026, Immutep reported cash, cash equivalents and term deposits of A$110.6 million, comprising about A$84.3 million in cash and cash equivalents and roughly A$26.3 million in bank term deposits.

Management stated at that time that this position was expected to provide a cash reach into the first half of calendar 2028, based on its assumptions. The company also flagged that the reported balance would be reduced by the wind-down costs associated with discontinuing TACTI-004, a reminder that stopping a large trial carries its own expenses. The cash runway had earlier been supported by a licensing transaction with Dr. Reddy's Laboratories, announced in December 2025, under which Immutep received an upfront payment and became eligible for potential milestone payments and royalties tied to efti in certain territories. As with any development-stage biotech, the runway is an estimate that can move with spending decisions, trial outcomes and any future capital raising.

Recent Announcements and Developments

The past several months have brought a run of substantive updates. The March 2026 discontinuation of TACTI-004 was the most consequential, removing what had been the company's flagship late-stage lung cancer programme and shifting attention toward efti's earlier data and the autoimmune pipeline.

In April 2026, Immutep said the U.S. Food and Drug Administration had granted Orphan Drug Designation for efti in soft tissue sarcoma, a status that can bring regulatory and financial benefits such as fee relief and a period of market exclusivity if a product is ultimately approved. In late May 2026, the company reported an analysis across multiple efti trials pointing to a median overall survival improvement in a defined responder group, though such retrospective analyses are hypothesis-generating rather than definitive. The June 2026 IMP761 data at EULAR then reinforced the autoimmune story. None of these items was dated to 13 July 2026, so while they help explain the current investment narrative, they do not constitute a fresh catalyst for the day's move.

Sector and Macro Backdrop

The wider market tone on 13 July 2026 was cautious. The S&P/ASX 200 was slightly lower in the morning after opening firmer, and defensive and growth-sensitive sectors were mixed. Energy stocks were among the stronger performers as oil prices rose on renewed Middle East tensions, while several rate-sensitive and gold-related names came under pressure.

Against that backdrop, Health Care was one of the softer sectors, down about 0.82% at the relevant snapshot. That makes Immutep's gain a divergence from its sector rather than a reflection of it. Smaller, speculative biotech stocks often trade on their own idiosyncratic drivers, including data expectations, sentiment and liquidity, rather than moving in lockstep with the broader index. In such an environment, a single low-priced stock can post an eye-catching gain even as the sector benchmark falls.

Why the Move May Matter

For existing holders, a sharp single-session rise can be encouraging, but it says little on its own about the company's fundamental trajectory. The more durable questions concern the strength of Immutep's remaining pipeline, the outcome of its root-cause review into efti, and the read-through from IMP761's early autoimmune data.

For prospective investors, the move is a reminder that stocks trading around six cents can be highly volatile, with percentage swings that overstate the underlying dollar change. Understanding that dynamic may help contextualise both the upside days and the inevitable down days that accompany speculative biotech exposure.

Positive Considerations and Potential Supports

On the constructive side, Immutep retains a reported cash and term deposit balance that management has characterised as funding operations into the first half of calendar 2028, which may reduce near-term financing pressure relative to peers with thinner reserves. The Dr. Reddy's licensing arrangement provides non-dilutive capital potential through upfront and possible milestone payments.

The company also retains multiple shots on goal. The IMP761 autoimmune programme has delivered early positive signals, efti has secured an orphan drug designation in soft tissue sarcoma, and the underlying LAG-3 science remains an area of active industry interest. These elements give the story more than one potential path forward, even after the setback in lung cancer.

Risks and Uncertainties

The risks are substantial and should be weighed carefully. Clinical risk is front of mind after the TACTI-004 discontinuation, which showed how quickly a lead late-stage asset can be sidelined; the root-cause review could carry implications for other efti studies. Early-stage data for IMP761, while encouraging, is no guarantee of success in larger trials, and many first-in-human signals do not replicate.

Funding and dilution risk persists for any pre-revenue biotech: cash runway estimates depend on assumptions, and a future capital raising could dilute existing shareholders. Regulatory risk is inherent in drug development, where approvals are never assured and timelines can extend. Finally, the stock's low price and speculative profile make it prone to sharp volatility, and a single-day surge with no confirmed catalyst can prove short-lived. None of the above should be read as advice; it is context for an inherently high-risk situation.

What Investors May Watch Next

Investors monitoring Immutep may look for the outcome of the efti root-cause review and any clarification of how the TACTI-004 result affects the wider efti programme. Further IMP761 data, including later readouts from its Phase I study, could shape sentiment on the autoimmune opportunity.

Balance-sheet updates in forthcoming quarterly activities reports will be relevant for tracking cash burn and runway, particularly given the wind-down costs of the discontinued trial. Any progress on partnering, milestone payments under the Dr. Reddy's agreement, or new trial plans may also feature. As always, watchers may distinguish confirmed announcements from market speculation.

Balanced Conclusion on Immutep (ASX: IMM)

Immutep Limited (ASX: IMM) delivered a striking morning gain of about 13.73% to $0.06 on 13 July 2026, standing out even as the Health Care sector traded lower. With no fresh company-specific catalyst identified at the time of writing, the move looks characteristic of a low-priced, speculative biotech rather than a response to new fundamental news. The company retains a meaningful cash position and a diversified LAG-3 pipeline, but it is also navigating the aftermath of a discontinued Phase III trial and the ordinary uncertainties of drug development. For those following the stock, the balance of near-term optimism and longer-term risk remains finely poised.